taking low-dose colchicine daily may slow the progression of a common acquired gene mutation found in the blood of older adults that can lead to certain blood cancers and increased risk of cardiovascular disease (cvd). this discovery opens new avenues for preventive treatment strategies.
the study focused on clonal hematopoiesis, a condition where blood cells acquire genetic mutations as people age. researchers found that colchicine, an anti-inflammatory medication traditionally used for gout treatment, demonstrated the ability to reduce the expansion of mutated blood cells by 40%.
this effect is believed to result from colchicine's unique mechanism of action on microtubules and inflammatory pathways. clinical trials showed a significant reduction in inflammatory markers associated with both clonal hematopoiesis and cardiovascular disease progression.
while the findings are promising, researchers caution that larger, long-term studies are needed to confirm the safety and efficacy of colchicine for this novel indication. current recommendations suggest that patients should not self-medicate and should consult healthcare providers before starting any treatment.
【全文结束】
